*Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; †Department of Public Health, Weill Cornell Medical College, Doha, Qatar; and ‡Department of Ophthalmology, Hotel Dieu de France, Saint Joseph's University, Beirut, Lebanon.
Retina. 2013 Oct;33(9):1828-35. doi: 10.1097/IAE.0b013e3182877a0d.
To study prospectively the safety and efficacy of intravitreal bevacizumab for eyes with neovascular age-related macular degeneration with baseline visual acuity better than 70 letters (Snellen equivalent better than 20/40).
Patients with treatment-naive neovascular age-related macular degeneration were categorized prospectively into three groups according to baseline visual acuity: Group 1 (better than 70 letters), Group 2 (70 to 61 letters), and Group 3 (60 to 51 letters). Best-corrected visual acuity and central retinal thickness using optical coherence tomography were measured at baseline and at each follow-up visit. Intravitreal bevacizumab was administered according to an as-needed optical coherence tomography-guided regimen. Main outcome measure was mean best-corrected visual acuity for each group at 12 months.
Each group included 30 patients (30 eyes). Improvement in central retinal thickness was similar among the 3 groups (P = 0.964). Mean letter gain in visual acuity at 12 months was +0.4, +3.8, and +4.2 for Groups 1, 2, and 3, respectively (P = 0.42). Mean best-corrected visual acuity at 12 months was 78.4 letters for Group 1, 70.0 letters for Group 2, and 61.1 letters for Group 3 (P < 0.001). All eyes in Group 1 (100%) avoided losing 15 letters of best-corrected visual acuity versus 83.3% in Group 2 and 80.0% in Group 3. This difference was significant only between Group 1 and Group 3 (P = 0.02).
Intravitreal bevacizumab for eyes with neovascular age-related macular degeneration and baseline visual acuity better than 70 letters was safe and able to maintain this vision over 12 months.
前瞻性研究玻璃体内注射bevacizumab 治疗基线视力优于 70 个字母（Snellen 视力表优于 20/40）的新生血管性年龄相关性黄斑变性的安全性和有效性。
根据基线视力将未经治疗的新生血管性年龄相关性黄斑变性患者前瞻性地分为三组：第 1 组（优于 70 个字母）、第 2 组（70 至 61 个字母）和第 3 组（60 至 51 个字母）。基线时和每次随访时使用光学相干断层扫描测量最佳矫正视力和中心视网膜厚度。根据光学相干断层扫描指导的需要，给予玻璃体内bevacizumab。主要观察指标为 12 个月时每组的平均最佳矫正视力。
每组均包括 30 例（30 只眼）。三组的中心视网膜厚度改善相似（P = 0.964）。12 个月时视力提高的平均字母数分别为第 1 组+0.4、第 2 组+3.8 和第 3 组+4.2（P = 0.42）。第 1 组 12 个月时的平均最佳矫正视力为 78.4 个字母，第 2 组为 70.0 个字母，第 3 组为 61.1 个字母（P<0.001）。第 1 组所有眼（100%）避免了最佳矫正视力丧失 15 个字母，而第 2 组为 83.3%，第 3 组为 80.0%。仅第 1 组与第 3 组之间的差异具有统计学意义（P = 0.02）。
玻璃体内注射 bevacizumab 治疗基线视力优于 70 个字母的新生血管性年龄相关性黄斑变性是安全的，能够在 12 个月内维持该视力。
